Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAAShell Companies
+$0.00 today
- Market cap
- $264.62M
- Beta
- 0.00
- P/E (TTM)
- 36.7
- EPS (TTM)
- $0.29
Volume 0.00M
Average 0.11M
DMAA Total Liabilities
Everything the company owes to creditors and other parties.
Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQ: DMAA
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities broadly unchanged from a year ago
Total liabilities stood at $7.39M at the end of Q1 FY2026, up 2.0% from a year earlier and up 1.6% from the prior quarter.
Context
- Total liabilities amounted to 3.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +2.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 7.28M USD
- Year-over-year change
- +914372.2%
- 1-year CAGR
- +914372.2%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.28M | +914372.2% |
| FY2024 | 2024-12-31 | 796 | — |
Total Liabilities vs competitors
How DMAA compares with its peers on the latest reported figures
- DMAA's Mar 2026 total liabilities of $7.39M is the 8th highest of the 10 companies compared; the peer median is $12.59M.
- Its year-over-year change of +2.0% is the 6th highest of 10, against a peer median of +131.6%.
- Total liabilities amounts to 3.1% of total assets for DMAA, versus a peer median of 4.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $32.19M | +131.6% | — | 13.3% | |
TACHTitan Acquisition Corp. | Mar 2026 | $14.27M | +1749367.7% | — | 4.9% |
| Mar 2026 | $13.84M | +0.2% | — | 4.5% | |
TACOUBerto Acquisition Corp. Unit | Mar 2026 | $12.59M | +985.7% | — | 4.0% |
| Mar 2026 | $12.59M | +985.7% | — | 4.0% | |
| Mar 2026 | $10.62M | -95.8% | — | 4.2% | |
OYSEOyster Enterprises II Acquisition Corp | Mar 2026 | $9M | +4469.4% | — | 3.4% |
| Mar 2026 | $7.39M | +2.0% | — | 3.1% | |
| Mar 2026 | $1.34M | -83.6% | -48.0% | 0.6% | |
| Mar 2026 | $768.22K | -93.0% | — | 0.3% | |
| Peer median (excluding DMAA) | $12.59M | +131.6% | -48.0% | 4.0% | |
Competitors are the stored peer set for DMAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Cash & Equivalents | 1.35K | 6.14K |
| Short-term Investments | 0 | 0 |
| Net Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Other Current Assets | 0 | 6.05K |
| Total Current Assets | 4.99K | 12.19K |
| Property, Plant & Equipment (Net) | 0 | 0 |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 0 |
| Long-term Investments | 0 | 0 |
| Tax Assets | 0 | 0 |
| Other Non-current Assets | 546 | 239.91M |
| Total Non-current Assets | 546 | 239.91M |
| Total Assets | 551 | 239.92M |
| Account Payables | 0 | 222.18K |
| Short-term Debt | 662 | 0 |
| Tax Payables | 0 | 0 |
| Deferred Revenue | 0 | 0 |
| Other Current Liabilities | 56 | 0 |
| Total Current Liabilities | 796 | 376.17K |
| Long-term Debt | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 |
| Other Non-current Liabilities | 0 | 6.9M |
| Total Non-current Liabilities | 0 | 6.9M |
| Total Liabilities | 796 | 7.28M |
| Common Stock | 986 | 239.91M |
| Retained Earnings | (279) | (7.27M) |
| Accumulated OCI | 0 | 0 |
| Other Stockholders Equity | (985) | 0 |
| Minority Interest | 0 | 0 |
| Total Equity | (244) | 232.64M |
| Total Debt | 662 | 0 |
| Net Debt | 661 | (6.14K) |
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAA
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.